GRTXD · Galera Therapeutics, Inc. · Executive Compensation
$18.99
At close · Aug 3
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern through the 12 months from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed May 14, 2026
Market Cap
$15.23M
Shares
802,149
Volume · Aug 3
2447
Avg daily vol (6 sessions)
1267
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $747,821 |
| Joel Sussman | Chief Accounting Officer, Treasurer and Secretary | $408,114 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $633,279 |
| Joel Sussman | Chief Accounting Officer, Treasurer and Secretary | $349,440 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $1,361,448 |
| Christopher Degnan | Chief Financial Officer | $834,865 |
| Mark Bachleda | Pharm.D., Chief Commercial Officer | $788,626 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,534,676 |
| Mark Bachleda | Pharm.D., Chief Commercial Officer | $1,288,415 |
| Christopher Degnan | Chief Financial Officer | $1,273,545 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,958,232 |
| Christopher Degnan | Chief Financial Officer | $1,458,593 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $1,449,913 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,465,102 |
| Christopher Degnan | Chief Financial Officer | $2,229,086 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $1,668,213 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $521,624 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $423,405 |
| Christopher Degnan | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Joel Sussman | Treasurer and Principal Financial and Accounting Officer | Resigned | 2026-08-04 |
| J. Mel. Sorensen | President and Principal Executive Officer | Resigned | 2026-08-04 |
| Parameswaran Hari | officers of the Company | Appointed | 2026-08-04 |
| Dana Alexander | officers of the Company | Appointed | 2026-08-04 |
| Julie Feder | officers of the Company | Appointed | 2026-08-04 |
| Madan Jagasia | officers of the Company | Appointed | 2026-08-04 |
| Kevin Lokay | Board | Resigned | 2026-08-04 |
| Lawrence Alleva | Board | Resigned | 2026-08-04 |
| Nancy Chang | Board | Resigned | 2026-08-04 |
| Michael Friedman | Board | Resigned | 2026-08-04 |
| J. Mel. Sorensen | Board | Resigned | 2026-08-04 |
| Michael Friedman | Class I director | Appointed | 2024-12-31 |
| Nancy Chang, Ph.D. | Class I director | Appointed | 2024-12-31 |
| Emmett Cunningham, M.D., Ph.D. | Class III director | Resigned | 2024-12-31 |
| Linda West | Class I director | Resigned | 2024-12-31 |
| Michael Powell, Ph.D. | Class I director | Resigned | 2024-12-31 |
| Christopher Degnan | Chief Financial Officer | Terminated | 2024-08-14 |
| Robert A. Beardsley | Chief Operating Officer | Terminated | 2024-06-07 |
| Mark Bachleda, Pharm.D. | Chief Commercial Officer | Terminated | 2023-08-10 |